Based on the CSL Ltd stock forecast from 0 analysts, the average analyst target price for CSL Ltd is not available over the next 12 months. CSL Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of CSL Ltd is Neutral, which is based on 8 positive signals and 7 negative signals. At the last closing, CSL Ltd’s stock price was AUD 276.57. CSL Ltd’s stock price has changed by -0.35% over the past week, +0.83% over the past month and -2.63% over the last year.
No recent analyst target price found for CSL Ltd
No recent average analyst rating found for CSL Ltd
Company Overview CSL Ltd
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia. Address: 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 Read Less
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL...Read More
Frequently Asked Questions About CSL Ltd (CSL:AU) Stock
Stock Target Advisor's fundamental analysis for CSL Ltd's stock is Neutral.
CSL:AU stock's dividend yield is 1.41%.
Our analysis grades CSL:AU stock's dividend yield at F. This means that CSL:AU stock's dividend yield is above 50% of the stocks in the Biotechnology sector in the AU exchange.
Based on this CSL:AU may be a average dividend stock for its sector.
Unfortunately we do not have enough data on CSL:AU's stock to indicate what its average analyst target is.
CSL:AU stock's Price/Earning ratio is 33.49.
Our analysis grades CSL:AU stock's Price / Earning ratio at F. This means that CSL:AU stock's Price/Earning ratio is above 60% of the stocks in the Biotechnology sector in the AU exchange.
Based on this CSL:AU may be a overvalued for its sector.
The last closing price of CSL:AU's stock was AUD 276.57.
The most recent market capitalization for CSL:AU is AUD 137.31B.
Unfortunately we do not have enough analyst data on CSL:AU's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains CSL Ltd's stock.
As per our most recent records CSL Ltd has 32,698 Employees.
CSL Ltd's registered address is 655 Elizabeth Street, Melbourne, VIC, Australia, 3000.
You can get more information about it from CSL Ltd's website at https://www.csl.com.au.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About CSL Ltd (CSL:AU) Stock
Stock Target Advisor's fundamental analysis for CSL Ltd's stock is Neutral.
CSL:AU stock's dividend yield is 1.41%.
Our analysis grades CSL:AU stock's dividend yield at F. This means that CSL:AU stock's dividend yield is above 50% of the stocks in the Biotechnology sector in the AU exchange.
Based on this CSL:AU may be a average dividend stock for its sector.
Unfortunately we do not have enough data on CSL:AU's stock to indicate what its average analyst target is.
CSL:AU stock's Price/Earning ratio is 33.49.
Our analysis grades CSL:AU stock's Price / Earning ratio at F. This means that CSL:AU stock's Price/Earning ratio is above 60% of the stocks in the Biotechnology sector in the AU exchange.
Based on this CSL:AU may be a overvalued for its sector.
The last closing price of CSL:AU's stock was AUD 276.57.
The most recent market capitalization for CSL:AU is AUD 137.31B.
Unfortunately we do not have enough analyst data on CSL:AU's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains CSL Ltd's stock.
As per our most recent records CSL Ltd has 32,698 Employees.
CSL Ltd's registered address is 655 Elizabeth Street, Melbourne, VIC, Australia, 3000.
You can get more information about it from CSL Ltd's website at https://www.csl.com.au.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CSL:AU !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
